John Kjekshus

Q: What Schools Are Affiliated With John Kjekshus

John Kjekshus is affiliated with the following schools: University of Oslo, Norwegian University of Science and Technology, University of Michigan, Baylor College of Medicine, University of Pittsburgh

John Kjekshus's AcademicInfluence.com Rankings

John Kjekshus

Philosophy

#3855

World Rank

#6158

Historical Rank

Logic

#1458

World Rank

#2215

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is John Kjekshus Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John Karsten Kjekshus is a Norwegian professor of medicine. He grew up at Solli. He took the Cand.med. degree in 1969 and the Dr.med. degree in 1972, both at the University of Oslo. He also studied at the University of California, San Diego from 1969 to 1970. He was a chief physician at Bærum Hospital from 1984 to 1992, then a professor at the University of Oslo and Rikshospitalet from 1992 to 2006. He chaired the Norwegian Cardiological Society from 1992 to 1994 and has chaired the National Association for Public Health from 2005. He is a member of the Norwegian Academy of Science and Letters since 1995 and was awarded the King's Medal of Merit in 2007.

(See a Problem?)

John Kjekshus's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. (1994) (6062)
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) (1999) (4830)
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. (2000) (4196)
Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). (1988) (4112)
[ESC/EAS Guidelines for the management of dyslipidaemias]. (2011) (3612)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (3071)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (2010) (1770)
ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction (1995) (1755)
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) (1997) (1715)
Factors Influencing Infarct Size Following Experimental Coronary Artery Occlusions (1971) (1553)
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. (2000) (1183)
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial (2002) (1159)
Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. (1990) (1136)
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (1103)
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) (1992) (977)
ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION (1992) (920)
Rosuvastatin in older patients with systolic heart failure. (2007) (905)
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) (1998) (648)
Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. (1998) (632)
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (2013) (605)
'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias. (2011) (596)
Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) (2000) (595)
Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. (1971) (582)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials (2015) (559)
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). (2004) (556)
Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) (1997) (508)
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. (1999) (471)
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). (1998) (463)
Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S (2001) (441)
Timolol‐related Reduction in Mortality and Reinfarction in Patients Ages 65‐75 Years Surviving Acute Myocardial Infarction (1982) (439)
[Expert Consensus document on beta-adrenergic receptor blockers]. (2004) (437)
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. (1997) (397)
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. (1997) (394)
Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. (1996) (378)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials (2018) (372)
Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. (1986) (368)
Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure (2001) (345)
Elevated circulating levels of C-C chemokines in patients with congestive heart failure. (1998) (344)
Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. (2004) (301)
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) (2004) (294)
Influence of heart rate on mortality after acute myocardial infarction. (1990) (283)
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. (1996) (277)
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. (2000) (275)
High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction (2017) (270)
Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. (2009) (256)
Arrhythmias and mortality in congestive heart failure. (1990) (251)
Depressed Myocardial Creatine Phosphokinase Activity Following Experimental Myocardial Infarction in Rabbit (1970) (248)
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). (2002) (246)
Diabetic patients and beta-blockers after acute myocardial infarction. (1990) (244)
-Blockers and Sudden Cardiac Death (1995) (239)
Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. (1999) (218)
Declining Risk of Sudden Death in Heart Failure (2017) (216)
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). (2009) (210)
Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. (1995) (207)
Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). (1992) (203)
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. (1996) (200)
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. (2004) (195)
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) (1996) (183)
Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) (1997) (180)
Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. (2017) (174)
Expert consensus document on beta-adrenergic receptor blockers. (2004) (171)
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). (2004) (169)
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). (1995) (168)
Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis (2009) (163)
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collab (2000) (161)
Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. (1972) (161)
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics (2005) (157)
Mechanism for Flow Distribution in Normal and Ischemic Myocardium during Increased Ventricular Preload in the Dog (1973) (153)
The Effect of Free Fatty Acids on Myocardial Oxygen Consumption During Atrial Pacing and Catecholamine Infusion in Man (1978) (152)
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). (2012) (152)
Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. (2001) (150)
Distribution of myocardial injury and its relation to epicardial ST-segment changes after coronary artery occlusion in the dog. (1972) (148)
Natriuretic peptides in patients with aortic stenosis. (2001) (143)
Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. (1999) (143)
Enhanced Expression of the Homeostatic Chemokines CCL19 and CCL21 in Clinical and Experimental Atherosclerosis: Possible Pathogenic Role in Plaque Destabilization (2007) (141)
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. (2012) (140)
Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: the Norwegian Nifedipine Multicenter Trial. (1984) (139)
Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study (1997) (138)
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. (2005) (133)
Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide (2009) (131)
Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. (1996) (125)
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). (2005) (119)
Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology (2012) (119)
Inflammatory imbalance between IL‐10 and TNFα in unstable angina potential plaque stabilizing effects of IL‐10 (2002) (117)
Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. (1990) (115)
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study (2009) (115)
Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. (2001) (114)
Effect of inhibition of lipolysis on infarct size after experimental coronary artery occlusion. (1973) (112)
Timolol Treatment After Myocardial Infarction in Diabetic Patients (1983) (110)
Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). (2014) (107)
Effects of losartan and captopril on mortality and morbidity after acute myocardial infarction: The OPTIMAAL randomized trial. (2002) (104)
Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. (1974) (103)
[Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease]. (2004) (100)
Tolerability of &bgr;-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) (2002) (97)
Effect of timolol on mortality and reinfarction after acute myocardial infarction: prognostic importance of heart rate at rest. (1986) (93)
Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. (2001) (93)
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of theEuropeanSocietyofCardiology(ESC)anddevelopedincollaboration (2014) (91)
Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. (2009) (91)
Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). (2010) (90)
Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes (2017) (89)
The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). (2009) (89)
The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). (2012) (87)
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. (2005) (83)
Cardiac output and its distribution through capillaries and A-V shunts in diving seals. (1983) (83)
Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. (2003) (83)
Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. (2004) (82)
Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction (2016) (82)
Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. (2001) (79)
Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. (1995) (79)
Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. (2001) (79)
Presence and development of atrial fibrillation in chronic heart failure (2006) (79)
Importance and management of chronic sleep apnoea in cardiology. (2013) (79)
Soluble CD40 ligand in acute and chronic heart failure. (2005) (76)
Sustained benefit of stenting chronic coronary occlusion: long-term clinical follow-up of the Stenting in Chronic Coronary Occlusion (SICCO) study. (1998) (76)
Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure: Results of a Double-Blind, Placebo-Controlled Study (2005) (76)
International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction (2015) (75)
The Relationship Between Cerebrospinal Fluid Creatine Kinase and Morphologic Changes in the Brain After Transient Cardiac Arrest (1980) (75)
Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group. (1992) (73)
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials (2015) (71)
Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. (2007) (70)
Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. (2006) (70)
Exercise capacity in heart transplant recipients: relation to impaired endothelium-dependent vasodilation of the peripheral microcirculation. (1998) (70)
Assessment of cerebral injury with spinal fluid creatine kinase (CSF-CK) in patients after cardiac resuscitation. (1980) (70)
Cardiovascular responses to face immersion and apnea during steady state muscle exercise. A heart catheterization study on humans. (1984) (68)
Putting low-density lipoproteins at center stage in atherogenesis. (1997) (66)
Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). (2001) (65)
Cholesterol and total mortality: need for larger trials. (1992) (65)
Compensatory mechanisms during graded myocardial ischemia. (1973) (64)
The association between neutrophil gelatinase‐associated lipocalin and clinical outcome in chronic heart failure: results from CORONA * (2011) (63)
The effect of magnesium versus verapamil on supraventricular arrhythmias (1993) (61)
Effect of folic acid treatment on endothelium-dependent vasodilation and nitric oxide-derived end products in hyperhomocysteinemic subjects. (2001) (60)
Prognostic Effect of High-Sensitive Troponin T Assessment in Elderly Patients With Chronic Heart Failure: Results From the CORONA Trial (2013) (60)
Heart rate reduction--a mechanism of benefit? (1987) (59)
Osteoprotegerin Predicts Progression of Chronic Heart Failure: Results From CORONA (2011) (58)
A double-blind, crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. (1984) (58)
HEART RATE AS A THERAPEUTIC TARGET IN HEART FAILURE (1999) (57)
Magnesium deficiency diagnosed by an intravenous loading test. (1992) (57)
Scandinavian simvastatin study (4S) (1994) (56)
Renal autoregulation during infusion of noradrenaline, angiotensin and acetylcholine. (1969) (55)
Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study. (1999) (55)
Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF) (1997) (54)
Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. (1997) (54)
Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer (2006) (52)
Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients. (2005) (50)
Myocardial blood flow in the diving seal. (1976) (50)
Relation of coronary artery calcium score to premature coronary artery disease in survivors >15 years of Hodgkin's lymphoma. (2010) (49)
The effect of free fatty acids on oxygen consumption in man: the free fatty acid hypothesis. (1980) (48)
Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure: Analysis From the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) (2013) (48)
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998. (1997) (48)
Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). (2009) (47)
[Calcium channel blockers in heart failure]. (1997) (47)
CXC‐chemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low‐density lipoprotein, platelets and peripheral blood mononuclear cells (2003) (46)
Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. (2001) (46)
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation (2004) (46)
The magnesium loading test: reference values in healthy subjects. (1994) (45)
Myocardial blood flow and metabolism in the diving seal. (1982) (45)
Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. (2013) (45)
An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT‐HF Substudy (2014) (44)
Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. (2001) (44)
Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). (2014) (43)
Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: A subgroup analysis from the cooperative north scandinavian enalapril survival study (CONSENSUS) (1994) (43)
Comments — Beta-blockers: Heart rate reduction a mechanism of benefit (1985) (42)
Effects of ACE2 inhibition in the post-myocardial infarction heart. (2010) (41)
Magnesium status in healthy free-living elderly Norwegians. (1994) (41)
Quantitative assessment of myocardial ischemia and necrosis by continuous vectorcardiography and measurement of creatine kinase release in patients. (1983) (39)
Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual‐level reanalysis of CORONA and GISSI‐HF (2015) (39)
Hospital discharge rates for nontraumatic lower extremity amputation by diabetes status--United States, 1997. (2001) (38)
Increased local metabolic rate by free fatty acids in the intact dog heart. (1971) (38)
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction (2015) (38)
Cardiac natriuretic peptides and continuously monitored atrial pressures during chronic rapid pacing in pigs. (2000) (37)
Exercise capacity of heart transplant recipients: the importance of chronotropic incompetence. (1996) (36)
Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarction. (2006) (36)
Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial. (2001) (35)
Inflammatory predictors of mortality in the scandinavian simvastatin survival study (2000) (34)
Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. (2017) (34)
Oral magnesium supplementation improves metabolic variables and muscle strength in alcoholics. (1992) (34)
Role of autoregulation in maintaining glomerular filtration rate at large urine flow. (1969) (34)
Local myocardial blood flow measured by hydrogen polarography; distribution and effect of hypoxia. (1967) (34)
Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocardium. (2009) (33)
Influence of guidewire and catheter type on the frequency of cerebral microembolic signals during left heart catheterization. (1998) (33)
The Homeostatic Chemokine CCL21 Predicts Mortality and May Play a Pathogenic Role in Heart Failure (2012) (32)
Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. (2013) (32)
Heart failure and statins—Why do we need a clinical trial? (2005) (31)
Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. (2019) (31)
Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). (2014) (30)
Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients. (2001) (30)
Predictors of exercise capacity and the impact of angiographic coronary artery disease in heart transplant recipients. (2004) (30)
Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease (2004) (30)
Tolerability of enalapril in congestive heart failure. (1988) (29)
Agents targeting inflammation in heart failure (2005) (29)
Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) (2015) (28)
An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure. (1998) (28)
The effect of aortic valve replacement on N‐terminal natriuretic propeptides in patients with aortic stenosis (2002) (28)
The Physiology of the Ureter and Renal Pelvis (1967) (28)
Patient characteristics in cases of chronic severe heart failure with different degrees of left ventricular systolic dysfunction. (1994) (27)
Beta-blockers and sudden cardiac death. (1995) (27)
Enalapril for congestive heart failure. (1989) (27)
Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA) (2010) (27)
Relationship between ventricular pressures and right and left myocardial blood flow. (1967) (27)
Coronary blood flow and myocardial segment dimensions during simulated dives in seals. (1985) (27)
[Treatment of acute myocardial infarction]. (1980) (27)
A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High‐Risk MI Database (2017) (26)
Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. (2005) (26)
Assessing the Role of Rare Genetic Variation in Patients With Heart Failure. (2020) (26)
Effect of timolol on late ventricular arrhythmias after acute myocardial infarction. (2009) (26)
Oxygen cost of sodium reabsorption in proximal and distal parts of the nephron. (1969) (24)
Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA) (2015) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. (2005) (23)
Effect of piboserod, a 5‐HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure (2009) (23)
Factors influencing infarct size following coronary artery occlusion. (1974) (23)
C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors? (2010) (22)
Temporal pattern of enzyme changes in cerebrospinal fluid in patients with neurologic complications after open heart surgery (1987) (22)
The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction (2014) (21)
Effects of selective beta 2-adrenoceptor blockade on serum potassium and exercise performance in normal men. (1991) (21)
Expert consensus document on b-adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology Task Force Members , Jos (2004) (21)
Atherosclerotic lesions in lymphoma survivors treated with radiotherapy. (2014) (21)
Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension (2002) (18)
An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial (2010) (18)
Fever after acute myocardial infarction in patients treated with intravenous timolol or placebo. (1987) (18)
Lipid-lowering therapy for patients with or at risk of coronary artery disease. (1996) (18)
Effect of timolol on changes in serum potassium concentration during acute myocardial infarction. (1985) (18)
Left ventricular volumes assessed by different new three-dimensional echocardiographic methods and ordinary biplane technique (1998) (17)
Difference between beta-1-selective and non-selective beta-blockade during continuous and intermittent exercise. (1988) (17)
Predicting 1-year outcome following acute myocardial infarction: physicians versus computers. (1990) (17)
Effect of Enalapril on Mortality in Congestive Heart Failure (2012) (17)
Beneficial effects of vagal stimulation on the ischaemic myocardium during beta-receptor blockade. (1981) (16)
Timolol maleate and HDL cholesterol after myocardial infarction. (1985) (16)
Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). (2014) (16)
Predictive Value of Endostatin in Chronic Heart Failure Patients with Poor Kidney Function (2014) (15)
Course of chest pain and its relation to CK release and ST/QRS vector changes in patients with acute myocardial infarction randomized to treatment with intravenous timolol or placebo. (1985) (15)
Differential responses of plasma atrial and brain natriuretic peptides to acute alteration in atrial pressure in pigs. (2000) (15)
Debate: Statins should be used in patients with heart failure (2001) (15)
Cardiac effects of isoproterenol during graded myocardial ischemia. (1974) (15)
Influence of the exercise protocol on hemodynamic, gas exchange, and neurohumoral responses to exercise in heart transplant recipients. (1996) (14)
Effect of inhibition of lipolysis on heart failure following acute coronary occlusion in the dog. (1974) (14)
The 4S Study (1994) (14)
Left ventricular mass assessed by three‐dimensional echocardiography using rotational acquisition (1997) (14)
How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). (2003) (14)
The perfect biomarker in acute coronary syndrome: a challenge for diagnosis, prognosis, and treatment. (2008) (14)
Acute and chronic hemodynamic effects of enalapril (MK-421) in congestive heart failure. (1984) (14)
Effect of rosuvastatin on fatigue in patients with heart failure. (2013) (13)
The importance of potassium and lactate for maximal exercise performance during beta blockade. (1989) (13)
Oral versus intravenous magnesium supplementation in patients with magnesium deficiency. (1991) (13)
How seals avoid myocardial infarction during diving: do they show us a new approach to treatment of patients with ischaemic heart injury? (1977) (12)
Pacing induced angina and platelet reactivity. (1982) (12)
769-4 Lowering of Cholesterol With Simvastatin may Prevent Development of Heart Failure in Patients With Coronary Heart Disease (1995) (12)
Quantitative and temporal relation between the release of myoglobin and creatine kinase and the evolution of vectorcardiographic changes during acute myocardial infarction in man. (1987) (12)
Platelet activation in heart transplant recipients. (2004) (12)
Overdrive suppression of implanted pacemakers in patients with AV block. (1978) (12)
Neuropeptide Y receptor 1 (NPY-Y1) expression in human heart failure and heart transplantation. (1998) (12)
Novel extracellular matrix biomarkers as predictors of adverse outcome in chronic heart failure: association between biglycan and response to statin therapy in the CORONA trial. (2015) (11)
The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA) (2014) (11)
Gas exchange and neurohumoral response to exercise: influence of the exercise protocol. (1997) (11)
Effects of glucagon and isoproterenol on severity of acute myocardial ischemic injury. (1973) (11)
Different prognostic importance of elevated troponin I after percutaneous coronary intervention in acute coronary syndrome and stable angina pectoris (2008) (11)
Mechanisms behind the postprandial increase in cardiac output: a clue obtained from transplanted hearts (2006) (11)
CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI‐HF trials (2013) (11)
Serial measurements of peripheral vascular reactivity and exercise capacity in congestive heart failure and after heart transplantation. (2005) (11)
Acute and long-term response to enalapril in congestive failure. (1984) (10)
Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure. (2018) (10)
Timolol-related reduction in mortality and reinfarction in diabetic patients surviving acute myocardial infarction. (1985) (10)
Sensitive cardiac troponins and N-terminal pro-B-type natriuretic peptide in stable coronary artery disease: correlation with left ventricular function as assessed by myocardial strain (2015) (10)
The impact of morbid events on survival following hospitalization for complicated myocardial infarction (2006) (10)
Angiotensin II receptor subtype AT1 and AT2 expression after heart transplantation. (1998) (10)
Impact of neurohormonal blockade on association between body mass index and mortality. (2007) (9)
Effect of timolol on platelet aggregation in coronary heart disease. (2009) (9)
Atrial natriuretic peptide ANP(1–98) and ANP(99–126) in patients with severe chronic congestive heart failure: Relation to echocardiographic measurements (1995) (9)
Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA) (2017) (9)
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S) (1998) (9)
[Angiotensin-converting enzyme inhibitors in heart failure]. (1987) (8)
Treating the diabetic patient with coronary disease. (1996) (8)
Evolution of vectorcardiographic QRS changes during myocardial infarction in dogs and their relation to infarct size. (1986) (8)
Tubular salt and water transport in hydrated dogs studied with push-flow technique. (1966) (8)
Effect of carbocromen induced coronary vasodilatation on myocardial metabolism in coronary artery disease (1978) (8)
A comparison of cumulated CK release with three vectorcardiographic methods of estimating myocardial infarct size. (1986) (7)
After Experimental Coronary Artery Occlusion (1973) (7)
Are statins failing in heart failure? (2015) (7)
PR Interval in middle‐aged men with overt and latent coronary heart disease compared to PR in angionegative and normal men of similar age (1982) (7)
Stenting in Chronic Coronary Occlusion (SICCO): A multicenter, randomized, controlled study (1996) (7)
Biochemical indices of cerebral ischemic injury. (1983) (7)
N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. (2003) (7)
Interaction of naloxone and timolol on maximal exercise capacity and the subjective perception of fatigue. (1989) (7)
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (6)
Depressed myocardial creatine phosphokinase activity following myocardial infarction (1970) (6)
Effect of increased afterload on the inotropic state and uptake of free fatty acids in the intact dog heart. (1972) (6)
[Immunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin]. (2001) (6)
Effect of beta-adrenergic blockade on hormonal responses during continuous and intermittent exercise (2005) (6)
[Myocardial disease in diabetes mellitus]. (1992) (6)
Treatment of heart failure (1996) (6)
Role of free fatty acids in catecholamine-induced cardiac necrosis. (1975) (6)
The statin wars (2003) (6)
Local metabolic rate and left ventricular oxygen consumption in the intact dog heart. (1971) (5)
Effects of prolonged hypotension on myocardial function in dogs. (1968) (5)
Left ventricular pressure and maximum rate of pressure rise as determinants of myocardial oxygen consumption during hemorrhagic hypotension in dogs. (1970) (5)
Faculty Opinions recommendation of Clinical Events After Discontinuation of β-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases. (2018) (5)
Lipid-Modifying Therapies and Risk of Pancreatitis (2012) (5)
Effect of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized clinical trial☆ (2003) (5)
Use of statins. Cost effectiveness was studied in 4S study. (1997) (5)
Power of plasma N-terminal proatrial natriuretic factor to determine haemodynamics in patients with cardiac disease: relation to serum creatinine. (1998) (5)
COMET: a proposed mechanism of action to explain the results and concerns about dose (2003) (5)
The european society of cardiology and the european atherosclerosis society (ESC/EAS) guidelines on the management of dyslipidemia (2011) (5)
901-76 Antagonism Between Enalapril and Aspirin: Subgroup Analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) (1995) (5)
How seals avoid myocardial infarction when they should have got it. (1984) (5)
The effects of naloxone and timolol on plasma catecholamine levels during short-term dynamic exercise. (1987) (5)
Effects of lipolytic and inotropic stimulation on myocardial ischemic injury. (2009) (5)
Assessment of myocardial injury with creatine phosphokinase (CPK). (1976) (5)
Sustained haemodynamic effects of enalapril in left ventricular failure. (1983) (5)
Is there a heart rate paradox – demystification of the myths? (2009) (4)
Exercise-induced vasodilation in healthy males: A marker of reduced endothelial function (2015) (4)
Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. (2017) (4)
Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure. (2013) (4)
SCANDINAVIAN SIMVASTATIN STUDY (4S). AUTHORS' REPLY (1994) (4)
Atrial natriuretic peptide ANP(1-98) and ANP(99-126) in patients with severe chronic congestive heart failure: relation to echocardiographic measurements. A subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). (1995) (4)
Achieved metoprolol CR/XL dose and clinical outcome Analysis of the experience in MERIT-HF (2001) (4)
According to MIAMI and ISIS-I trials, can a general recommendation be given for beta blockers in acute myocardial infarction? (1988) (3)
[Magnesium and cardiovascular diseases]. (1986) (3)
Heart rate, heart rhythm and prognostic benefits of beta-blockers in heart failure: individual patient-data meta-analysis (2017) (3)
Haemodynamics during repeated exercise tests with special reference to the 'warm-up' phenomenon in patients with angina pectoris. (1987) (3)
Effect of penbutolol (Hoe 893 d) and practolol on exercise-induced angina pectoris 2 and 24 hours after a single oral dose (1978) (3)
The importance of pre‐ and postinfarction angina on timolol‐related reduction in mortality and reinfarction (1985) (3)
CT examination of the pericardium and lungs in helicopter pilots exposed to vibration and noise. (2012) (3)
Abstract 2370: LDL Independent Reduction In Cardiovascular Morbidity And Mortality With Rosuvastatin In Heart Failure Patients With A Raised C-reactive Protein: A Retrospective Analysis Of The Controlled Rosuvastatin Multinational Trial In Heart Failure (CORONA) (2008) (3)
Cerebrospinal fluid creatine kinase isoenzyme BB levels do not predict the clinical outcome in patients unconscious following cardiac resuscitation. (1988) (3)
Monday, 27 August 2012 (2012) (3)
Inflammation: Friend and Foe (2015) (3)
[Inhalation of a prostacyclin analog (iloprost) in primary and secondary pulmonary hypertension]. (2001) (3)
M-Mode Echocardiography in Patients with Severe Congestive Heart Failure (2012) (2)
Letters to the Editor (2007) (2)
Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. (2007) (2)
Nitrates in Acute Myocardial Infarction (2012) (2)
ACE inhibitors after myocardial infarction. (1993) (2)
Effect of thyroxin on myocardial function and oxygen consumption (1968) (2)
Cholesterol and total mortality (1992) (2)
Effect of immunomodulating therapy with intravenous immunglobulin in chronic heart failure (2000) (2)
CARDIAC ADAPTATIONS IN DIVING SEALS1 (1981) (2)
Loss of prazosin effect in severe chronic CHF. (2009) (2)
Effect of ACE-Inhibition on regional blood flow during acute left ventricular failure in the dog. Preliminary report. (1984) (2)
Effects of Bed Rest and Prazosin in Congestive Heart Failure (2009) (2)
Abstract 18355: Predictors of Fatigue in Heart Failure (2012) (2)
PREDICTION OF BRAIN DAMAGE BY BRAIN ENZYME LEVELS IN CEREBROSPINAL FLUID (CSF) OF PATIENTS AFTER GLOBAL OR FOCAL ISCHEMIA (1984) (2)
Escape Rhythm in Complete A‐V Block. The Recovery Phase after Overdrive Suppression from Artificial Ventricular Pacing (1979) (2)
Effect of inhibition of lipolysis on acute myocardial injury during coronary occlusion in normal and reserpinized dogs. (2009) (2)
Redistribution of peripheral blood flow during acute left ventricular failure in the dog. (1988) (1)
Electrocardiographic mapping of ischaemic myocardial insult. (2009) (1)
A protective anti-inflammatory phenotype in high-risk individuals who do not develop coronary artery disease. (2006) (1)
P4392Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status (2017) (1)
Effect of ACE-inhibition on tissue blood flow during acute left ventricular failure in the dog (1987) (1)
The statin wars. Author's reply (2003) (1)
Risk associated with statin treatment. (2008) (1)
[Sudden cardiac death. Significance of beta blockaders]. (1992) (1)
The OPTIMAAL trial: losartan or captopril after acute myocardial infarction (2002) (1)
581 Etanercept or intravenous immunoglobulin attenuates right and left ventricular post‐myocardial infarction remodeling in rats (2005) (1)
[Intermittent claudication and beta-blockaders. An unfortunate combination?]. (1995) (1)
599 C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors? (2010) (1)
Time course of morbidity and mortality after a myocardial infarction complicated by left ventricular systolic dysfunction or heart failure (2003) (1)
[Chronic heart failure--suggestion to a management program]. (1999) (1)
Subject Index Vol. 16 (Suppl 2), 1984 (1984) (1)
Faculty Opinions recommendation of The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. (2019) (1)
What are the effects of patient age and blood pressure on the cholesterol-related risk of vascular mortality? (2008) (1)
Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failu (2015) (1)
Artery Occlusions Factors Influencing Infarct Size Following Experimental Coronary (2011) (1)
Ace Inhibitors in Heart Failure. (1984) (1)
Comparison of inflammatory activation and restenosis after percutaneous coronary intervention in heart transplant recipients and patients with stable angina pectoris (2004) (0)
ICSV 14 Cairns • Australia 9-12 July , 2007 ACUTE EFFECT OF A HELICOPTER FLIGHT ON CELLULAR TISSUE BIOCHEMICAL MARKERS (2007) (0)
Angiotensin II receptor subtype AT and AT expression after heart 1 2 transplantation (1998) (0)
A helicopter flight does not induce significant changes in systemic biomarker profiles (2009) (0)
Distribution of myocardial injury and its relation to epicardial ST-segment change after coronary occlusion in the dog. (2000) (0)
Recurrent Infarction Causes the Most Deaths Following Myocardial Infarction With Left Ventricular Dysfunction (2005) (0)
Commentary Debate: Statins should be used in patients with heart failure (2001) (0)
Abstract 15613: Re-Analysis of Landmark Statin Trials in Heart Failure Patients Using Competing Risks Methods (2013) (0)
Escape rhythm in complete A-V block. The recovery phase after overdrive suppression from artificial ventricular suppression from artificial ventricular pacing. (1979) (0)
730 The effect of Piboserod a 5‐HT4‐receptor antagonist on left ventricular function in patients with symptomatic heart failure (2008) (0)
Statins and Heart Failure - Reply (2010) (0)
Increase in Anti-Inflammatory Cytokine Levels in Chronic Heart Failure: A Measure of Treatment Success (2001) (0)
DOES FEMALE SEX INFLUENCE HEART FAILURE AND SUDDEN DEATH AFTER MYOCARDIAL INFARCTION (2011) (0)
[Prevention--are we not good enough?]. (1997) (0)
Level of Consciousness Grade Description 0 Awake I Drowsy but responding to verbal commands II Responding to mild painful stimulation III Minimum response to maximal painful stimulation IV No response to maximal painful stimulation (2005) (0)
The multifactorial approach to myocardial salvage. The experience from diving seals. (2009) (0)
Abstract 18269: Prognostic Value of Insulin-Like Growth Factor Binding Protein 7 (IGFBP7) in Patients With Heart Failure: Data From CORONA (2013) (0)
Effects of red rest and prazosin in congestive heart failure. (1982) (0)
NT-proBNP keeps its predictive ability during several years of follow-up (2009) (0)
[Treatment of hypercholesterolemia in adults. An action plan]. (1988) (0)
Effect of Ace-Inhibition on Regional Blood Flow During Acute Left Ventricular Failure in the Dog. (1984) (0)
Panel Discussion: The Role of Nitrates in the Medical Treatment of Heart Disease (1987) (0)
[Treatment of chronic heart failure]. (1992) (0)
vectorcardiography and measurement of creatine kinase release in patients Quantitative assessment of myocardial ischemia and necrosis by continuous (2011) (0)
Abstract 16715: Symptoms as Predictors of Outcome in Patients With Heart Failure in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) (2013) (0)
Clinical Investigations The Effects of Simvastatin on the Incidence of Heart Failure in Patients With Coronary Heart Disease (1997) (0)
Abstract 68th Meeting of the European Atherosclerosis Society Molecular Cell Biology and Atherogenesis21 Lipid changes and reductions in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) (1997) (0)
Acute Ischemic Heart Disease Sensitive troponin assays and N-terminal pro – B-type natriuretic peptide in acute coronary syndrome : Prediction of significant coronary lesions and long-term prognosis (2013) (0)
Hematinics in Patients with Complicated Acute Myocardial Infarction: Results from an OPTIMAAL Substudy (2008) (0)
rognostic Value of Osteoprotegerin in eart Failure After Acute Myocardial Infarction (2016) (0)
[Reduction of cholesterol prevents disease]. (1996) (0)
Poster Session 4: Friday 9 December 2011, 14:00-18:00 * Location: Poster Area (2011) (0)
[Prazosin in exercise-induced angina pectoris. An open study of work capacity after a single dose of prazosin, isosorbide dinitrate, atenolol and nifedipine]. (1984) (0)
[Cholesterol depression prevents heart disease]. (1997) (0)
Atrial natriuretic peptide in patients with severe congestive heart failure in relation to M-mode echocardiographic measurements (1991) (0)
ACE Inhibitors in heart failure. (1984) (0)
Chapter 5 – Secondary Prevention of Atherosclerosis and Related Events by Statins (2004) (0)
661 Innate immunity in heart failure following acute myocardial infarction (2005) (0)
ž / Neuropeptide Y receptor 1 NPY-Y 1 expression in human heart failure and heart transplantation (0)
[Determining the blood flow through the myocardium in patients]. (1971) (0)
[Magnesium deficiency. Diagnosis and occurrence of different disease conditions]. (1987) (0)
Feverafter acutemyocardial infarction inpatients treated withintravenous timolol or placebo (1987) (0)
Cardiovascular Responses to Combined Apnoea and Face Immersion in Exercising Man (1982) (0)
The coronary circulation in normal and ischemic hearts. (1984) (0)
[Reduced physical tolerance in patients with heart failure. Mechanisms and therapeutic effects]. (1995) (0)
The influende of renal function on clinical outcome and response to beta-blockade in Systolic heart failure : Insights from MERIT-HF (2007) (0)
[Beta blockaders and physical performance. Limiting factors]. (1989) (0)
' s response to reviews Title : The Impact of Coronary Artery Disease Risk Loci on Ischemic Heart Failure Severity and Prognosis : Data from the COntrolled ROsuvastatin multiNAtional trial in heart failure ( CORONA ) (2014) (0)
University of Birmingham Impact of renal impairment on beta-blocker efficacy in patients with heart failure (2020) (0)
[Use of beta-blockaders in heart failure]. (2003) (0)
Mechanisms in the maintenance of glomerular filttion rate during high urine flow. (1969) (0)
Composition for treatment of heart failure (2001) (0)
Heart Failure/Cardiac Transplantation Plasma C-Reactive Protein as a Marker of Cardiac Allograft Vasculopathy in Heart Transplant Recipients (2003) (0)
[Lipid reduction--benefit without risk?]. (1997) (0)
[Myocardial function and oxygen consumption in hypertension]. (1968) (0)
Abstract 10904: The Seattle Post Myocardial Infarction Model (SPIM): Prediction of Mortality after Acute Myocardial Infarction (2012) (0)
[Current use of beta-blockers in coronary artery disease]. (1999) (0)
Sex Male Female Clinical history Previous infarction Typical angina Typical or suspected angina Secondary diagnosis angina Treated hypertension Smoking Therapy before admission Digitalis Diuretics Beta blockers Risk factor for this study Heart failure Enlarged heart Lowest systolic BP (2005) (0)
Total homocysteine levels predicts major coronary events and mortality in simvastatin treated patients of 4S (2001) (0)
Acuteandlong-term response toenalapril incongestive failure (1984) (0)
[Cardio-reparation--or cardioversion]. (1996) (0)
Baseline lipid and lipoprotein values and the effect of simvastatin on mortality in the Scandinavian simvastatin survival study (4S) (1995) (0)
A U-SHAPED RELATIONSHIP BETWEEN TOTAL CHOLESTEROL AND 90-DAY MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION IN PATIENTS NOT ON STATINS: RESULTS FROM THE OPTIMAAL RANDOMIZED TRIAL (2011) (0)
intravenous timolol or placebo . infarction in patients treated with Fever after acute myocardial (2005) (0)
[ProANF and heart failure in general practice]. (1996) (0)
[Treatment of heart failure with beta-blockaders]. (1997) (0)
[Chronic heart failure. A management program. Proposal for diagnosis and treatment]. (1994) (0)
GuidelinesESC/EAS Guidelines for the Management of Dyslipidaemias (2013) (0)
1WS02-6 Treatment with statin and beta-blockers in high risk patients with acute myocardial infarction (2003) (0)
Contents to volume 15 (1986) (0)
AN INVESTIGATION INTO THE EFFECT OF CYTOCHROME P450 (CYP) 2D6 GENOTYPE ON PHARMACOKINETICS, PHARMACODYNAMICS AND OUTCOMES DURING METOPROLOL CR/XL THERAPY IN A HEART FAILURE COHORT: A MERIT-HF SUB-STUDY (2013) (0)
Overdrive suppression ofimplanted pacemakers inpatients with AVblock (1978) (0)
Population responsibility in general practice (1996) (0)
[Automatic implantable defibrillator. A method for the treatment of life-threatening arrhythmias]. (1985) (0)
[Chronic left heart ventricle failure and inotropic stimulation]. (1995) (0)
Volume Contents (2007) (0)
[Unexpected sudden death after percutaneous coronary intervention]. (2006) (0)
[Treatment of heart failure--life and doctrine]. (1994) (0)
Abstract 18013: Which Measure of Renal Function is the Best Predictor of Outcome in Heart Failure? A Comparison of Cockcroft Gault, Modification of Diet in Renal Disease Study Group and Chronic Kidney Disease Epidemiology Collaboration Formulae (2013) (0)
The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction (2013) (0)
University of Groningen Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Beta-Blockers Heart Failure (0)
AN INVESTIGATION INTO THE EFFECT OF CYTOCHROME P450 (CYP) 2D6 GENOTYPE ON PHARMACOKINETICS, PHARMACODYNAMICS AND OUTCOMES DURING METOPROLOL CR/XL THERAPY IN A HEART FAILURE COHORT (2013) (0)
fficacy, safety and tolerability of metoprolol CR/XL n patients with diabetes and chronic heart failure: xperiences from MERIT-HF (2004) (0)
Abstract 18454: Novel Extracellular Matrix Biomarkers as Predictors of Adverse Outcome in Chronic Heart Failure (2013) (0)

This paper list is powered by the following services:

Other Resources About John Kjekshus

en.wikipedia.org

What Schools Are Affiliated With John Kjekshus?

John Kjekshus is affiliated with the following schools: